Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Application of interferon modulators to overcome partial resistance of human ovarian cancers to VSV-GP oncolytic viral therapy.

Dold C, Rodriguez Urbiola C, Wollmann G, Egerer L, Muik A, Bellmann L, Fiegl H, Marth C, Kimpel J, von Laer D.

Mol Ther Oncolytics. 2016 Sep 28;3:16021. eCollection 2016.

2.

C peptides as entry inhibitors for gene therapy.

Egerer L, Kiem HP, von Laer D.

Adv Exp Med Biol. 2015;848:191-209. doi: 10.1007/978-1-4939-2432-5_10. Review.

PMID:
25757622
3.

VSV-GP: a potent viral vaccine vector that boosts the immune response upon repeated applications.

Tober R, Banki Z, Egerer L, Muik A, Behm├╝ller S, Kreppel F, Greczmiel U, Oxenius A, von Laer D, Kimpel J.

J Virol. 2014 May;88(9):4897-907. doi: 10.1128/JVI.03276-13. Epub 2014 Feb 19.

4.

A rationally engineered anti-HIV peptide fusion inhibitor with greatly reduced immunogenicity.

Brauer F, Schmidt K, Zahn RC, Richter C, Radeke HH, Schmitz JE, von Laer D, Egerer L.

Antimicrob Agents Chemother. 2013 Feb;57(2):679-88. doi: 10.1128/AAC.01152-12. Epub 2012 Nov 12.

5.

Secreted antiviral entry inhibitory (SAVE) peptides for gene therapy of HIV infection.

Egerer L, Volk A, Kahle J, Kimpel J, Brauer F, Hermann FG, von Laer D.

Mol Ther. 2011 Jul;19(7):1236-44. doi: 10.1038/mt.2011.30. Epub 2011 Mar 1.

6.

Mutations in gp120 contribute to the resistance of human immunodeficiency virus type 1 to membrane-anchored C-peptide maC46.

Hermann FG, Egerer L, Brauer F, Gerum C, Schwalbe H, Dietrich U, von Laer D.

J Virol. 2009 May;83(10):4844-53. doi: 10.1128/JVI.00666-08. Epub 2009 Mar 11.

7.

Woodchuck hepatitis virus post-transcriptional regulatory element deleted from X protein and promoter sequences enhances retroviral vector titer and expression.

Schambach A, Bohne J, Baum C, Hermann FG, Egerer L, von Laer D, Giroglou T.

Gene Ther. 2006 Apr;13(7):641-5.

PMID:
16355114

Supplemental Content

Loading ...
Support Center